- Home
- PDI vs LEGN Comparison
PDI vs LEGN Comparison
Compare PDI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDI
- LEGN
- Stock Information
- Founded
- PDI 2012
- LEGN 2014
- Country
- PDI United States
- LEGN United States
- Employees
- PDI N/A
- LEGN N/A
- Industry
- PDI Trusts Except Educational Religious and Charitable
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- PDI Finance
- LEGN Health Care
- Exchange
- PDI Nasdaq
- LEGN Nasdaq
- Market Cap
- PDI 6.6B
- LEGN 6.0B
- IPO Year
- PDI N/A
- LEGN 2020
- Fundamental
- Price
- PDI $19.12
- LEGN $34.67
- Analyst Decision
- PDI
- LEGN Strong Buy
- Analyst Count
- PDI 0
- LEGN 13
- Target Price
- PDI N/A
- LEGN $80.62
- AVG Volume (30 Days)
- PDI 1.5M
- LEGN 1.3M
- Earning Date
- PDI 01-01-0001
- LEGN 03-10-2025
- Dividend Yield
- PDI 13.81%
- LEGN N/A
- EPS Growth
- PDI N/A
- LEGN N/A
- EPS
- PDI N/A
- LEGN N/A
- Revenue
- PDI N/A
- LEGN $520,183,000.00
- Revenue This Year
- PDI N/A
- LEGN $121.04
- Revenue Next Year
- PDI N/A
- LEGN $67.39
- P/E Ratio
- PDI N/A
- LEGN N/A
- Revenue Growth
- PDI N/A
- LEGN 122.96
- 52 Week Low
- PDI $15.45
- LEGN $30.17
- 52 Week High
- PDI $19.60
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- PDI 62.51
- LEGN 50.64
- Support Level
- PDI $18.56
- LEGN $30.17
- Resistance Level
- PDI $19.02
- LEGN $37.92
- Average True Range (ATR)
- PDI 0.14
- LEGN 2.19
- MACD
- PDI 0.08
- LEGN 0.31
- Stochastic Oscillator
- PDI 97.25
- LEGN 58.06
About PDI PIMCO Dynamic Income Fund
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investments include mortgage-backed securities, investment grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.